Neither atezolizumab plus chemotherapy nor atezolizumab alone improved overall survival when compared to chemotherapy alone in patients with advanced urothelial cancer in the phase 3 IMvigor130 trial. Neither atezolizumab plus chemotherapy nor atezolizumab alone improved OS when compared to chemotherapy alone in patients with advanced urothelial cancer.